DEVELOPING 3D PRINTING MODELS OF BRAIN TUMOURS

Abstract AIMS To succeed in clinical trials for glioblastoma we need vitro models capable of more faithfully replicating dis- ease biology and accurately predicting patient drug responses. this end, new bioprinting technologies have the potential to biofabricate clinically relevant biomimetic tissues which can accelerate discovery additionally serve as a platform personalized medicine. METHOD We evaluated effect individual biomaterials combinations biomaterials, including decellularised pig brain extracellular matrix (dECM), fibrin, gelatin-methacryloyl (GelMA), hyaluronic acid-methacrylate (HAMA), Matrigel alginate, on proliferation invasion aggressive cancer cells (U87) vitro. Cell viability was assessed using propidium iodide. Invasiveness studied employing confocal microscopy. Data generated from Z-stacks analysed ImageJ determine size circularity cells. RESULTS Although supports rapid cell invasion, it has mechanical properties unsuited bio- printing. In contrast, HAMA displays pronounced shear-thinning behaviour controllable photo- crosslinking. Combinations HAMA-fibrin provided results comparable those seen with or HAMA- Matrigel. However, high levels crosslinking affected these biomaterial mixtures, resulting decreased ability grow spread. CONCLUSIONS Initial indicate that addition fibrin promoted growth spreading U87 further work, aim improve our printed constructs by porcine dECM, microglia recently established lines paediatric patients. The project will test whether bioprinted provide testing data closer human disease than current, simpler alternatives.